Sellas’ cancer vaccine extends survival in blood cancer trial, company says

Sellas’ cancer vaccine extends survival in blood cancer trial, company says

The company plans to talk ‌to the U.S. Food ​and Drug Administration about seeking approval ⁠for the vaccine. Image used for representational purposes only | Photo Credit: Getty Images Sellas Life ‌Sciences said on Tuesday, November 17, 2026 that its ​experimental ⁠vaccine helped patients with a type of blood ‌cancer live longer in ‌a late-stage ‌trial.The ⁠vaccine, called galinpepimut-S ⁠or GPS, was tested in patients with acute ​myeloid ‌leukaemia, a fast-growing cancer of the blood and bone marrow.Patients ‌who received ​GPS lived a median of ⁠24 months, compared to 14.7 months ‌for those given the best available treatment, Sellas said.The company plans to talk ‌to the U.S. Food ​and Drug Administration about seeking approval ⁠for the vaccine. ⁠Its shares were halted in premarket ‌trading. Published - November 19, 2026 04:35 pm IST

Original Source

Read the full article at Thehindu →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.